Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBT Margin: 2009-2025

Historic EBT Margin for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -86.15%.

  • China Pharma Holdings' EBT Margin rose 1546.00% to -86.15% in Q3 2025 from the same period last year, while for Sep 2025 it was -78.72%, marking a year-over-year increase of 685.00%. This contributed to the annual value of -104.58% for FY2024, which is 6067.00% down from last year.
  • China Pharma Holdings' EBT Margin amounted to -86.15% in Q3 2025, which was down 67.25% from -51.51% recorded in Q2 2025.
  • China Pharma Holdings' 5-year EBT Margin high stood at -24.28% for Q1 2023, and its period low was -155.48% during Q2 2024.
  • Moreover, its 3-year median value for EBT Margin was -69.13% (2025), whereas its average is -74.58%.
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by 10,147bps in 2024, then soared by 10,397bps in 2025.
  • China Pharma Holdings' EBT Margin (Quarterly) stood at -33.94% in 2021, then plummeted by 934bps to -43.28% in 2022, then slumped by 1,404bps to -57.32% in 2023, then crashed by 5,065bps to -107.98% in 2024, then skyrocketed by 1,546bps to -86.15% in 2025.
  • Its last three reported values are -86.15% in Q3 2025, -51.51% for Q2 2025, and -69.13% during Q1 2025.